JP2013525285A - 化合物の送達を増強するための方法および組成物 - Google Patents

化合物の送達を増強するための方法および組成物 Download PDF

Info

Publication number
JP2013525285A
JP2013525285A JP2013503991A JP2013503991A JP2013525285A JP 2013525285 A JP2013525285 A JP 2013525285A JP 2013503991 A JP2013503991 A JP 2013503991A JP 2013503991 A JP2013503991 A JP 2013503991A JP 2013525285 A JP2013525285 A JP 2013525285A
Authority
JP
Japan
Prior art keywords
composition
molecules
homing
molecule
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013503991A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013525285A5 (cg-RX-API-DMAC10.html
Inventor
エリキ ロスラッティー,
ライラック アゲミー,
ダイノラ フリードマン−モルビンスキー,
ベンカッタ ラマナ コタムラジュ,
一樹 菅原
インデル ベルマ,
Original Assignee
サンフォード−バーナム メディカル リサーチ インスティテュート
ザ ソルク インスティチュート オブ バイオロジカル スタディーズ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サンフォード−バーナム メディカル リサーチ インスティテュート, ザ ソルク インスティチュート オブ バイオロジカル スタディーズ filed Critical サンフォード−バーナム メディカル リサーチ インスティテュート
Publication of JP2013525285A publication Critical patent/JP2013525285A/ja
Publication of JP2013525285A5 publication Critical patent/JP2013525285A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013503991A 2010-04-08 2011-04-08 化合物の送達を増強するための方法および組成物 Pending JP2013525285A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32220710P 2010-04-08 2010-04-08
US61/322,207 2010-04-08
US37685610P 2010-08-25 2010-08-25
US61/376,856 2010-08-25
PCT/US2011/031785 WO2011127405A1 (en) 2010-04-08 2011-04-08 Methods and compositions for enhanced delivery of compounds

Publications (2)

Publication Number Publication Date
JP2013525285A true JP2013525285A (ja) 2013-06-20
JP2013525285A5 JP2013525285A5 (cg-RX-API-DMAC10.html) 2014-05-15

Family

ID=44120964

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013503991A Pending JP2013525285A (ja) 2010-04-08 2011-04-08 化合物の送達を増強するための方法および組成物

Country Status (5)

Country Link
US (2) US20110262347A1 (cg-RX-API-DMAC10.html)
EP (1) EP2555802A1 (cg-RX-API-DMAC10.html)
JP (1) JP2013525285A (cg-RX-API-DMAC10.html)
CA (1) CA2795289A1 (cg-RX-API-DMAC10.html)
WO (1) WO2011127405A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017527554A (ja) * 2014-08-19 2017-09-21 ノースウェスタン ユニバーシティ タンパク質/オリゴヌクレオチドコアシェルナノ粒子治療薬
US10837018B2 (en) 2013-07-25 2020-11-17 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10363309B2 (en) * 2011-02-04 2019-07-30 Case Western Reserve University Targeted nanoparticle conjugates
WO2012135550A1 (en) * 2011-03-30 2012-10-04 Luna Innovations Incorporated Biomarker-targeting contrast agents and their use in magnetic resonance imaging for detection of atherosclerotic plaque
US20130116404A1 (en) 2011-11-08 2013-05-09 Case Western Reserve University Targeted non-invasive imaging probes of egfr expressing cells
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
US20130217765A1 (en) * 2012-02-16 2013-08-22 Eric Brown Multifunctional nanoconjugates and uses thereof
EP2671597A1 (en) * 2012-06-07 2013-12-11 Cepep III AB Chimeric constructs between glioma-homing peptide and cell-penetrating peptides, gHoPe2
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN106794217A (zh) * 2014-08-06 2017-05-31 血管生物科学 包含对患病组织具有选择性的药效团的组合物及其制备方法
BR112017007012A2 (pt) 2014-10-06 2018-03-06 Exicure Inc compostos anti-tnf
EP3017809A1 (en) * 2014-11-07 2016-05-11 Ferring B.V. Drug-device unit containing quinagolide
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016172515A1 (en) 2015-04-23 2016-10-27 Sanford Burnham Prebys Medical Discovery Institute Targeted delivery system and methods of use therefor
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN105055315B (zh) * 2015-08-03 2017-10-31 四川大学 一种交联线粒体靶向阿霉素脂质体及其制备方法
CN106220735A (zh) * 2015-09-11 2016-12-14 中山大学 一种组织蛋白酶b激活式靶向抗肿瘤多肽的制备与应用
CN105395483B (zh) * 2015-12-21 2018-09-28 江南大学 一种可还原降解超支化聚合物纳米胶束及其制备方法
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018085050A1 (en) 2016-11-03 2018-05-11 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for imaging tissues and tumors
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2017384425B2 (en) 2016-12-21 2023-08-31 Nanobiotix Nanoparticles for use for treating a neuronal disorder
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN111712468A (zh) 2017-12-22 2020-09-25 北卡罗莱纳州立大学 聚合物荧光团、包含其的组合物及制备和使用其的方法
WO2019183633A1 (en) 2018-03-23 2019-09-26 Case Western Reserve Univeristy Psma targeted conjugate compounds and uses thereof
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020190556A1 (en) * 2019-03-18 2020-09-24 Novomer, Inc. Membrane separation system, and uses thereof
WO2021242917A1 (en) * 2020-05-27 2021-12-02 Georgetown University Targeting the cholecystokinin-b receptor for imaging and early detection of pancreatic cancer and pre-cancerous lesions
US20250332265A1 (en) 2021-11-09 2025-10-30 Case Western Reserve University Psma targeted conjugate compounds and uses thereof
CN114106108B (zh) * 2021-11-25 2023-07-14 中国石油大学(华东) 一种多肽-金纳米颗粒复合物、其制备方法及应用
CN114732796B (zh) * 2022-02-18 2023-01-17 北京大学第三医院(北京大学第三临床医学院) 一种双靶向载药微泡及其制备方法和应用
WO2025186514A1 (en) * 2024-03-07 2025-09-12 University Of Helsinki Cancer cell targeting peptide
WO2026150165A1 (en) * 2025-01-09 2026-07-16 Tampere University Foundation Sr Tissue-penetrating homing peptides, peptide conjugates and compositions comprising the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535258A (ja) * 1999-01-22 2002-10-22 ザ バーナム インスティチュート ホーミングプロアポトーシス結合体およびホーミングプロアポトーシス結合体を使用する方法
WO2003087124A2 (en) * 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
JP2005514348A (ja) * 2001-11-08 2005-05-19 ザ バーナム インスティチュート 腫瘍リンパ性脈管構造を目指すペプチドおよびその使用方法
WO2008085794A2 (en) * 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
US20090036349A1 (en) * 2006-12-06 2009-02-05 Erkki Ruoslahti Methods and Compositions Related to Targeting Wounds, Regenerating Tissue, and Tumors
WO2009105671A2 (en) * 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1016978B (de) 1955-05-16 1957-10-03 Iashellia Res Ltd Mittel zur Bekaempfung des Pflanzenwachstums
FR1601438A (cg-RX-API-DMAC10.html) 1968-10-17 1970-08-24
CH588887A5 (cg-RX-API-DMAC10.html) 1974-07-19 1977-06-15 Battelle Memorial Institute
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4418052A (en) 1980-08-12 1983-11-29 Wong Dennis W Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
GB8416234D0 (en) 1984-06-26 1984-08-01 Ici Plc Biodegradable amphipathic copolymers
US4761288A (en) 1984-09-24 1988-08-02 Mezei Associates Limited Multiphase liposomal drug delivery system
US5628936A (en) 1987-03-13 1997-05-13 Micro-Pak, Inc. Hybrid paucilamellar lipid vesicles
US5474848A (en) 1987-03-13 1995-12-12 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4853228A (en) 1987-07-28 1989-08-01 Micro-Pak, Inc. Method of manufacturing unilamellar lipid vesicles
US5011686A (en) 1987-09-21 1991-04-30 Creative Biomolecules, Inc. Thrombus specific conjugates
US5013497A (en) 1988-03-03 1991-05-07 Micro-Pak, Inc. Method and apparatus for producing lipid vesicles
US5024829A (en) 1988-11-21 1991-06-18 Centocor, Inc. Method of imaging coronary thrombi
JP2517760B2 (ja) 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5792742A (en) 1991-06-14 1998-08-11 New York University Fibrin-binding peptide fragments of fibronectin
FR2735658B1 (fr) 1995-06-21 1997-09-12 Capsulis Encapsulation de composes a usage alimentaire par des tensioactifs
KR940003548U (ko) 1992-08-14 1994-02-21 김형술 세탁물 건조기
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CA2163860A1 (en) 1993-06-30 1995-01-12 Chung C. Hsu Method for preparing liposomes
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
US5789542A (en) 1994-04-22 1998-08-04 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Amphipathic peptides
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
JP4036472B2 (ja) 1995-04-14 2008-01-23 一則 片岡 片末端に糖、他末端に異なる官能基を有するポリエチレンオキシド及びその製造方法
KR19990007861A (ko) 1995-04-19 1999-01-25 가타오카가즈노리 헤테로테레케릭 블록 공중합체 및 이의 제조방법
WO1997006202A1 (en) 1995-08-10 1997-02-20 Kazunori Kataoka Block polymer having functional groups at both ends
US5897945A (en) 1996-02-26 1999-04-27 President And Fellows Of Harvard College Metal oxide nanorods
US6506564B1 (en) 1996-07-29 2003-01-14 Nanosphere, Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US6576239B1 (en) 1996-09-10 2003-06-10 The Burnham Institute Angiogenic homing molecules and conjugates derived therefrom
GB9708265D0 (en) 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
KR20000076363A (ko) 1997-03-18 2000-12-26 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 Dna 라이브러리를 제조하기 위한 시험관내 방법
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
NZ508669A (en) 1998-06-11 2003-06-30 Dimensional Pharm Inc Pyrazinone protease inhibitors
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
ATE346074T1 (de) 2000-11-30 2006-12-15 Penn State Res Found Dna methyl transferase inhibitoren
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
US7544767B2 (en) 2002-04-05 2009-06-09 Burnham Institute For Medical Research HMGN2 peptides and related molecules that selectively home to tumor blood vessels and tumor cells
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
US7723474B2 (en) * 2003-10-21 2010-05-25 The Regents Of The University Of California Molecules that selectively home to vasculature of pre-malignant dysplastic lesions or malignancies
CN103169729A (zh) * 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
WO2007090194A2 (en) 2006-02-01 2007-08-09 The Burnham Institute For Medical Research Lymphatic zip codes in tumors and pre-malignant lesions
WO2008100328A2 (en) 2006-07-13 2008-08-21 Burnham Institute For Medical Research METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32
US8367621B2 (en) 2008-01-18 2013-02-05 Sanford-Burnham Medical Research Institute Methods and compositions related to internalizing RGD peptides
US20100254914A1 (en) * 2009-02-25 2010-10-07 The Regents Of The University Of California Nanoworms for in vivo tumor targeting
CN102869384B (zh) 2009-06-22 2016-01-13 伯纳姆医学研究所 使用带有c-端元件的肽和蛋白质的方法和组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002535258A (ja) * 1999-01-22 2002-10-22 ザ バーナム インスティチュート ホーミングプロアポトーシス結合体およびホーミングプロアポトーシス結合体を使用する方法
JP2005514348A (ja) * 2001-11-08 2005-05-19 ザ バーナム インスティチュート 腫瘍リンパ性脈管構造を目指すペプチドおよびその使用方法
WO2003087124A2 (en) * 2002-04-05 2003-10-23 The Burnham Institute Hmgn2 peptides and related melecules that selectively home to tumor blood vessels and tumor cells
US20090036349A1 (en) * 2006-12-06 2009-02-05 Erkki Ruoslahti Methods and Compositions Related to Targeting Wounds, Regenerating Tissue, and Tumors
WO2008085794A2 (en) * 2007-01-03 2008-07-17 Burnham Institute For Medical Research Methods and compositions related to clot binding compounds
WO2009105671A2 (en) * 2008-02-21 2009-08-27 Burnham Institute For Medical Research Methods and compositions related to peptides and proteins with c-terminal elements cross-reference to related applications

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5013005647; MAEKELAE ANNA: 'ENHANCED BACULOVIRUS-MEDIATED TRANSDUCTION OF HUMAN CANCER CELLS BY TUMOR-HOMING PEPTIDES' JOURNAL OF VIROLOGY V80 N13, 200607, P6603-6611 *
JPN6014050095; Cancer Cell. Nov; 4(5), 2003, p.383-391 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10837018B2 (en) 2013-07-25 2020-11-17 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10894963B2 (en) 2013-07-25 2021-01-19 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
JP2017527554A (ja) * 2014-08-19 2017-09-21 ノースウェスタン ユニバーシティ タンパク質/オリゴヌクレオチドコアシェルナノ粒子治療薬

Also Published As

Publication number Publication date
WO2011127405A1 (en) 2011-10-13
CA2795289A1 (en) 2011-10-13
EP2555802A1 (en) 2013-02-13
US20110262347A1 (en) 2011-10-27
WO2011127405A9 (en) 2011-11-17
US20170246236A1 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
US20170246236A1 (en) Methods and compositions for enhanced delivery of compounds
US20260048133A1 (en) Methods and compositions using peptides and proteins with c-terminal elements
US12195558B2 (en) Targeted delivery system and methods of use therefor
US20120034164A1 (en) Truncated car peptides and methods and compositions using truncated car peptides
JP6184101B2 (ja) アネキシン1結合化合物に関する方法および組成物
US20240391953A1 (en) Tumor associated monocyte/macrophage binding peptide and methods of use thereof
CN102016058A (zh) 与具有c端元件的肽和蛋白相关的方法和组合物
US10179801B2 (en) Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US8912136B2 (en) Methods and compositions related to clot-binding compounds
AU2020218940B2 (en) Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2012118778A1 (en) Truncated car peptides and methods and compositions using truncated car peptides
US20130058993A1 (en) Methods and compositions for enhancing wound healing using car peptides
Janib Development of positron emission tomography (PET) labeled polypeptide nanoparticles for tumor imaging and targeting

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140328

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141125

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150313

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151210